In the first half of 2023, Ipsen reported a 7.4% increase in total sales at constant exchange rates, driven by strong growth in its growth-platforms sales, which rose by 17.7% with the contribution of newly acquired medicines. However, sales of Somatuline® declined by 12.0%. The company’s core operating margin decreased to 34.0% due to investments in the pipeline, including Bylvay® and Tazverik®. The IFRS operating margin was 19.2%, reflecting integration costs and amortization of intangible assets from recent acquisitions. Ipsen made favorable developments in its pipeline through the acquisition of Albireo and advancements in various products. The company upgraded its 2023 financial guidance, expecting total-sales growth greater than 6.0% at CER and a core operating margin greater than 30.0% of total sales, compared to previous guidance of greater than 4.0% at CER and around 30% for the core operating margin.
ordres du jour, comptes rendus, questions d’actionnaires
La seule qui repose sur la présence effective à TOUS les rendez-vous des sociétés cotées : assemblées générales annuelles et extraordinaires, présentations de résultats semestriels et annuels, investor days
La veille de l'HebdodesAG
La seule veille qui repose sur la présence effective à TOUS les rendez-vous de 700 sociétés cotées en France et à l'étranger : assemblées générales annuelles et extraordinaires, présentations de résultats semestriels et annuels, investor days
IPSEN, July 27th 2023
Date de publication :27/07/2023